Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2523483 | 1.00 | BACE1 (0.64) | BACE1CTSD | |
| SCHEMBL6845741 | 1.00 | BACE1 (0.64) | BACE1CTSD | |
| SCHEMBL16109784 | 0.90 | BACE1 (0.65) | BACE1CTSD | |
| SCHEMBL16109783 | 0.90 | BACE1 (0.65) | BACE1CTSD | |
| SCHEMBL1999311 | 0.89 | BACE1 (0.70) | BACE1CTSD | |
| SCHEMBL2522511 | 0.89 | BACE1 (0.70) | BACE1CTSD | |
| SCHEMBL1999314 | 0.89 | BACE1 (0.70) | BACE1CTSD | |
| SCHEMBL12471764 | 0.85 | BACE1 (0.71) | BACE1CTSD | |
| SCHEMBL12686672 | 0.85 | BACE1 (0.71) | BACE1CTSD | |
| SCHEMBL12686611 | 0.85 | BACE1 (0.71) | BACE1CTSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9777019-B2 | Amino-oxazine and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use | AMGEN INC. (US) | 2017-10-03 | — | — | US | disclosed |
| US-9777019-B2 | Amino-oxazine and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use | AMGEN INC. (US) | 2017-10-03 | — | — | US | disclosed |
| US-9777019-B2 | Amino-oxazine and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use | AMGEN INC. (US) | 2017-10-03 | — | — | US | disclosed |
| US-9725469-B2 | Amino-oxazine and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use | AMGEN, INC. (US) | 2017-08-08 | — | — | US | disclosed |
| US-9725469-B2 | Amino-oxazine and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use | AMGEN, INC. (US) | 2017-08-08 | — | — | US | disclosed |
| US-9725469-B2 | Amino-oxazine and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use | AMGEN, INC. (US) | 2017-08-08 | — | — | US | disclosed |
| US-20160159818-A1 | Amino-Oxazine and Amino-Dihydrothiazine Compounds as Beta-Secretase Modulators and Methods of Use | AMGEN INC. (US) | 2016-06-09 | — | — | US | disclosed |
| US-20160159818-A1 | Amino-Oxazine and Amino-Dihydrothiazine Compounds as Beta-Secretase Modulators and Methods of Use | AMGEN INC. (US) | 2016-06-09 | — | — | US | disclosed |
| US-20160159818-A1 | Amino-Oxazine and Amino-Dihydrothiazine Compounds as Beta-Secretase Modulators and Methods of Use | AMGEN INC. (US) | 2016-06-09 | — | — | US | disclosed |
| US-9296759-B2 | Amino-oxazine and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use | AMGEN INC. (US) | 2016-03-29 | — | — | US | disclosed |
| US-20140045828-A1 | AMINO-OXAZINES AND AMINO-DIHYDROTHIAZINE COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | AMGEN INC. | 2014-02-13 | — | — | US | disclosed |
| US-20140045828-A1 | AMINO-OXAZINES AND AMINO-DIHYDROTHIAZINE COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | AMGEN INC. | 2014-02-13 | — | — | US | disclosed |
| US-20140045828-A1 | AMINO-OXAZINES AND AMINO-DIHYDROTHIAZINE COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | AMGEN INC. | 2014-02-13 | — | — | US | disclosed |
| EP-2547686-B1 | AMINO-DIHYDROOXAZINE AND AMINO-DIHYDROTHIAZINE SPIRO COMPOUNDS AS BETA-SECRETASE MODULATORS AND THEIR MEDICAL USE | AMGEN INC (US) | 2014-01-22 | — | — | EP | disclosed |
| US-8497264-B2 | Amino-oxazines and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use | AMGEN INC. (US) | 2013-07-30 | — | — | US | disclosed |
| WO-2013044092-A1 | AMINO-OXAZINES AND AMINO-DIHYDROTHIAZINE COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2013-03-28 | — | — | WO | disclosed |
| US-20110251186-A1 | Amino-Oxazines and Amino-Dihydrothiazine Compounds as Beta-Secretase Modulators and Methods of Use | AMGEN INC. (US) | 2011-10-13 | — | — | US | disclosed |
| US-20110251186-A1 | Amino-Oxazines and Amino-Dihydrothiazine Compounds as Beta-Secretase Modulators and Methods of Use | AMGEN INC. (US) | 2011-10-13 | — | — | US | disclosed |
| US-20110251186-A1 | Amino-Oxazines and Amino-Dihydrothiazine Compounds as Beta-Secretase Modulators and Methods of Use | AMGEN INC. (US) | 2011-10-13 | — | — | US | disclosed |
| WO-2011115928-A1 | AMINO -DIHYDROOXAZINE AND AMINO - DIHYDROTHIAZINE SPIRO COMPOUNDS AS BETA - SECRETASE MODULATORS AND THEIR MEDICAL USE | AMGEN INC. (US) | 2011-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160159818-A1 | Amino-Oxazine and Amino-Dihydrothiazine Compounds as Beta-Secretase Modulators and Methods of Use | BACE1, APP, BACE2 | BACE1 1/4885CTSD 2039/4885 |
| US-20140045828-A1 | AMINO-OXAZINES AND AMINO-DIHYDROTHIAZINE COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | BACE1, APP, BACE2 | BACE1 1/4885CTSD 1985/4885 |
| US-20110251186-A1 | Amino-Oxazines and Amino-Dihydrothiazine Compounds as Beta-Secretase Modulators and Methods of Use | BACE1, APP, BACE2 | BACE1 1/4885CTSD 1985/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.